Clinical Trials in Boston

Showing 5741-5760 of 13,548 trials

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

NCT02378038

This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with Richter's Transformation.

Richter's Transformation

Sierra Oncology LLC - a GSK company5 participantsStarted Aug 2015

Orange, California, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +6 more locations

COMPLETEDPhase 2< 1 mile

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

NCT01216683

RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. It is not yet known whether giving bendamustine hydrochloride and rituximab together alone is more effective than giving bendamustine hydrochloride and rituximab together with bortezomib or lenalidomide in treating follicular lymphoma. PURPOSE: This randomized phase II trial is studying giving bendamustine hydrochloride and rituximab together with or without bortezomib followed by rituximab with or without lenalidomide to see how well they work in treating patients with high-risk stage II, stage III, or stage IV follicular lymphoma.

Lymphoma

ECOG-ACRIN Cancer Research Group289 participantsStarted Feb 2011

Greenbrae, California, United States • Salinas, California, United States • Stanford, California, United States +224 more locations

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Find Trials by Condition in Boston

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

VAXCHORA Pediatric Study to Assess Safety and Immunogenicity

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

MP1032 Treatment in Patients With Moderate to Severe COVID-19

Study of Verinurad in Heart Failure With Preserved Ejection Fraction

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection

A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19